Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Authors: Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink, Bin Du, Gabrielle Poirier, Khurram Rana, Alita A. Miller, Drew Lewis, John P. O’Donnell, Lan Chen, Harald H. Reinhart, Subasree Srinivasan, Robin Isaacs, David Altarac - The Lancet 2023 cited by 286